Sera Prognostics, Inc. (NASDAQ:SERA) CEO Sells $32,950.06 in Stock

Sera Prognostics, Inc. (NASDAQ:SERA - Get Free Report) CEO Zhenya Lindgardt sold 23,042 shares of the business's stock in a transaction that occurred on Monday, June 9th. The shares were sold at an average price of $1.43, for a total value of $32,950.06. Following the transaction, the chief executive officer now directly owns 844,209 shares in the company, valued at approximately $1,207,218.87. This represents a 2.66% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Zhenya Lindgardt also recently made the following trade(s):

• On Tuesday, June 10th, Zhenya Lindgardt sold 3,344 shares of Sera Prognostics stock. The shares were sold at an average price of $1.48, for a total value of $4,949.12.
• On Thursday, May 8th, Zhenya Lindgardt sold 9,406 shares of Sera Prognostics stock. The shares were sold at an average price of $2.44, for a total value of $22,950.64.

Sera Prognostics Stock Performance

Sera Prognostics stock traded down $0.07 during mid-day trading on Friday, hitting $1.71. The company's stock had a trading volume of 392,256 shares, compared to its average volume of 152,866. Sera Prognostics, Inc. has a one year low of $1.37 and a one year high of $9.13. The stock has a market cap of $64.42 million, a PE ratio of -1.73 and a beta of 0.71. The company has a 50 day moving average of $2.47 and a 200-day moving average of $4.61.

Sera Prognostics (NASDAQ:SERA - Get Free Report) last issued its earnings results on Wednesday, May 14th. The company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.24) by $0.04. The firm had revenue of $0.04 million during the quarter, compared to analysts' expectations of $0.06 million. On average, equities research analysts forecast that Sera Prognostics, Inc. will post -0.96 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen downgraded Sera Prognostics from a "hold" rating to a "sell" rating in a research report on Friday, June 6th.

Institutional Investors Weigh In On Sera Prognostics

Several hedge funds have recently made changes to their positions in the company. Aberdeen Group plc purchased a new stake in shares of Sera Prognostics during the 1st quarter worth $4,563,000. AWM Investment Company Inc. lifted its stake in shares of Sera Prognostics by 48.1% during the 1st quarter. AWM Investment Company Inc. now owns 866,837 shares of the company's stock worth $3,190,000 after purchasing an additional 281,703 shares during the last quarter. Wealth Enhancement Advisory Services LLC purchased a new stake in shares of Sera Prognostics during the 4th quarter worth $1,285,000. Perkins Capital Management Inc. purchased a new stake in shares of Sera Prognostics during the 1st quarter worth $522,000. Finally, Ghisallo Capital Management LLC purchased a new stake in shares of Sera Prognostics during the 1st quarter worth $368,000. 54.64% of the stock is currently owned by hedge funds and other institutional investors.

About Sera Prognostics

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.